Dr. Sung Park, who has held the role of Vice President at GC LabTech (GCLT) and the Vice President and General Manager of GCAM, was named the Chief Executive Officer (CEO) of both GCAM and GCLT last month.
Dr. Park has been working with the Green Cross family of businesses for the past 14 years and brings a vast knowledge of the pharma industry.
GCAM looks forward to all of its employees welcoming Dr. Park for another smooth transition into his new role.
GCAM, Inc. (GCAM) is dedicated to and specializes in the plasma industry. Our facilities are licensed and regulated by the Food and Drug Administration (FDA), and both Federal and State agencies routinely inspect the centers.
GCAM operates multiple plasma collection centers across the United States. Annually we produce approximately 500,000 liters of plasma that meet FDA facilities and quality standards and in turn supply this to Green Cross.
Green Cross is a biopharmaceutical company headquartered in Yongin, South Korea. They specialize in the development and commercialization of vaccines, plasma-derivatives, recombinant proteins, and therapeutic antibodies for use in the fields of oncology and infectious disease.
GCAM was established to secure a stable supply of plasma as raw material for plasma fractionation products and enter the U.S. market according to the global strategy of Green Cross.
GCAM, Inc. (GCAM) is an affiliate company of GC Pharma, which became the first company in South Korea and the sixth company in the world to establish a plasma fractionation plant in 1971. GCAM and GC Pharma are a part of the Green Cross Holdings Corporation, which manufactures medicines and medical supplies. GCAM’s centers pride themselves on providing a pleasant, relaxing environment and its focus on donor safety and satisfaction.